04.02.2026
Bridging the Gap Between AI and Immunity: Alithea Bio Named UN AI for Good Finalist
The Frontier of Precision Medicine
In a world where healthcare often takes a “one size fits all” approach, Alithea Bio is using Artificial Intelligence to usher in the era of truly personalized medicine. We are proud to announce that Alithea Bio has been selected as a finalist for the UN-based AI for Good Innovation Factory pitching competition: “Top Startups Advancing Accessible and Affordable Healthcare Solutions.”
Hosted by the International Telecommunication Union (ITU), this global stage recognizes startups using AI and machine learning to solve the world’s most pressing health challenges. For Alithea Bio, this is an opportunity to showcase how AI-driven biotechnology can make high-end cancer treatment more precise, safe, and accessible.
Why Alithea Bio?
Our platform doesn’t just analyze data; it analyzes biology. We specialize in HLA peptide discovery—the critical “identification tags” that allow the immune system to recognize and destroy diseased cells.
Our immunopeptidomics platform doesn’t just analyze data; it analyzes biology. We specialize in HLA peptide discovery—the critical “identification tags” that allow the immune system to recognize and destroy diseased cells.
Our Core Innovations:
-
AI-Driven Safety Assessment: Using our HLA-Compass platform, we leverage the world’s largest quantitative database to predict “off-target” toxicity, ensuring new therapies attack cancer, not the patient.
-
High-Sensitivity Discovery: Our NeoZoom pipeline identifies rare targets for cancer vaccines that traditional methods miss.
-
Accelerating R&D: By automating the most complex parts of target validation, we reduce the time and cost of bringing life-saving immunotherapies to market.
The Future of Biotech: Scaling AI for Good
The role of AI for Good in biotechnology extends beyond simple data processing; it is about democratizing access to the most advanced medical treatments available. Traditionally, developing precision immunotherapy was a process that took decades and billions of dollars. By using machine learning to predict how the immune system will react to specific peptides, Alithea Bio is lowering the barrier to entry for life-saving drugs.
When we talk about AI for Good, we are talking about a shift from reactive medicine to proactive, predictive healthcare. Our platform allows researchers to “test” the safety of a drug in a digital environment before it ever reaches a human trial, significantly increasing the success rate of clinical studies and reducing risks for patients.
A Mission for Global Impact
The AI for Good movement is dedicated to ensuring that AI benefits all of humanity. At Alithea Bio, we align with this mission by creating tools that make the development of Precision Immunotherapy more efficient. When drug development becomes more predictable through AI, costs go down, and access goes up—even in low-resource settings.
“Being recognized by the United Nations and the ITU reinforces our commitment to using AI as a force for global health equity.”
The Road to Geneva 🇨🇭
As a finalist, Alithea Bio is competing for a spot at the AI for Good Global Summit 2026 Grand Finale in Geneva. This journey is about more than just a trophy; it’s about joining a global ecosystem of innovators, investors, and UN partners dedicated to solving global challenges.
Join Us Online
Join Us Online Witness the future of healthcare innovation by attending the AI for Good Webinar.
-
Date: Tuesday, 3 February 2026
-
Time: 16:00 – 17:00 CET
-
Platform: Online, hosted by ITU
